Could a triple chemo cocktail beat standard care for tough rectal cancers?
NCT ID NCT07472868
First seen Mar 23, 2026 · Last updated May 08, 2026 · Updated 8 times
Summary
This study compares two chemotherapy approaches for people with high-risk locally advanced rectal cancer. One group gets a stronger three-drug combo (FOLFOXIRI) before chemoradiation, while the other gets a standard two-drug combo (CAPOX/FOLFOX). The goal is to see if the stronger combo leads to more complete tumor disappearance, better quality of life, and improved long-term outcomes, even though it may cause more side effects. About 394 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Catharina Hospital Eindhoven
Eindhoven, North Brabant, 5623 EJ, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.